The present invention relates to selected bacterial strains belonging to the genus Lactobacillus and the use thereof for the treatment of bacterial biofilms and, specifically, for preventive treatment aimed at inhibiting and/or reducing the formation of bacterial biofilms. In particular, the present invention relates to the following bacterial strains belonging to the genus Lactobacillus selected from the group comprising or, alternatively, consisting of Lactobacillus plantarum LMC1 (DSM 32252), Lactobacillus reuteri LMC3 (DSM 32253), Lactobacillus paracasei LMC4 (DSM 32254), Lactobacillus reuteri LMCS (DSM 32255), Lactobacillus rhamnosus LMC6 (DSM 32256), Lactobacillus rhamnosus LMC7 (DSM 32257), Lactobacillus paracasei LMC8 (DSM 32258), Lactobacillus reuteri LMC9 (DSM 32259) and Lactobacillus rhamnosus LMC10 (DSM 32260) and the use thereof for the treatment of bacterial biofilms and, specifically, for preventive treatment aimed at inhibiting and/or reducing the formation of bacterial biofilms. Furthermore, the present invention relates to a pharmaceutical composition, a composition for a medical device or a composition for dietary supplements comprising a mixture which comprises or, alternatively, consists of one or more of the bacterial strains specified above and, optionally, pharmaceutical or food grade technological additives and/or excipients, for the treatment of bacterial biofilms and, specifically, for preventive treatment aimed at inhibiting and/or reducing the formation of bacterial biofilms.
